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Abstract
Purpose The purpose of the study was to evaluate the efficacy
of preoperative intravenous (IV) ferric carboxymaltose (FCM)
administration vs. no-IV iron in colon cancer (CC) anemic
patients undergoing elective surgery with curative intention.
Methods This was a multicenter, observational study includ-
ing two cohorts of consecutive CC anemic patients: the no-IV
iron treatment group was obtained retrospectively while
FCM-treated patients were recorded prospectively.
Results A total of 266 patients were included: 111 received
FCM (median dose 1000 mg) and 155 were no-IV iron sub-
jects. Both groups were similar in terms of demographic char-
acteristics, tumor location, surgical approach, and intra-
operative bleeding severity. The FCM group showed a signif-
icant lower need for red blood cell (RBC) transfusion during
the study (9.9 vs. 38.7 %; OR: 5.9, p<0.001). In spite of lower
hemoglobin levels at baseline diagnosis and lower transfusion
rates in the FCM group, the proportion of responders was
significantly higher with respect to the no-IV group both at
hospital admission (48.1 vs. 20.0%, p<0.0001) and at 30 days
post-surgery (80.0 vs. 48.9 %, p<0.0001). The percentage of
patients with normalized hemoglobin levels was also higher in
the FCM group (40.0 vs. 26.7 % at 30 days, p<0.05). A lower
number of reinterventions and post-surgery complications
were seen in the FCM group (20.7 vs. 26.5 %; p=0.311).
The FCM group presented a significant shorter hospital stay
(8.4±6.8 vs. 10.9±12.4 days to discharge; p<0.001).
Conclusions Preoperative ferric carboxymaltose treatment in
patients with CC and iron deficiency anemia significantly re-
duced RBC transfusion requirements and hospital length of
stay, reaching higher response rates and percentages of nor-
malized hemoglobin levels both at hospital admission and
30 days post-surgery.
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Introduction
A large number of different tumors occur associated with ane-
mia, which ranges from 25–75 % in cancer patients who un-
dergo surgery [1]. Although differing by tumor location, the
overall prevalence of anemia in colon cancer was around 48%
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with moderate to severe anemia found in more than 20 % of
cases [2]. The etiology of anemia in cancer patients is typically
multifactorial, mainly caused by systemic inflammation with
increased hepcidin levels promoted by the tumor itself as well
as by iron deficiency due to gastrointestinal blood loss that
occurs in association with tumor ulceration and with malnu-
trition derived from the disease itself [3, 4]. Besides, blood
losses can be stressed during the surgery.
Preoperative anemia is emerging as a common and impor-
tant health problem [5]. This condition is extremely common
before surgery associated with colorectal cancer (up to 70 %
of patients) [6, 7] and has also been demonstrated in associa-
tion with increased postoperative morbi-mortality and dura-
tion of hospitalization as well as with reduced quality of life
[5, 7–10]. Anemia might contribute to complications during
and post-surgery [6, 7, 9]. In addition, a low preoperative
hemoglobin concentration is one of the major risk factors for
transfusion in surgery with moderate to high blood losses [5,
6, 10]. Jointly, the perioperative transfusions unfavorably af-
fect patient outcomes and highlight the risk of postoperative
infections, surgical reintervention, recurrence-metastasis, and
subsequent cancer-related mortality in colorectal cancer sur-
gery [6, 11, 12]. Therefore, in the context of elective surgery, it
is advisable as far as possible to detect and evaluate preoper-
ative anemia early enough to start a suitable treatment.
Anemia in this patient population is largely due to absolute
or functional iron deficiency. As such, administering iron prior
to surgery is considered an appropriate treatment [13, 14].
Most anemic patients are treated with oral iron, although this
therapeutic procedure is slow in terms of iron absorption rate
and, in the context of a surgical cancer patient, clearly insuf-
ficient to restore early enough the hemoglobin levels and for
iron deposit repositioning [14, 15]. However, parenteral ad-
ministration of iron could increase up to five times the eryth-
ropoietic response, which is also associated with a lower fre-
quency of adverse effects in comparison with blood transfu-
sions [13, 16, 17].
Previous studies have shown that treatment with intrave-
nous iron administered at least 1 week before surgery in-
creases hemoglobin levels and, consequently, should reduce
the need for transfusion of red blood cell (RBC) units during
the perioperative period [18–20]. Therefore, the implementa-
tion of intravenous iron administration protocols appears to be
an effective and safe strategy for the treatment of preoperative
anemia and possibly to reduce transfusion requirements and
hospitalization in patients scheduled for elective surgery while
meeting cost-effectiveness criteria, whenever an early detec-
tion and diagnosis of preoperative anemia is achieved with the
objective to implement this therapeutic choice [13, 14, 21].
Many unsustained misconceptions constitute a barrier to this
approach [15].
With this background in mind and considering the lack of
studies with a significant number of patients with colon cancer
(CC), this study was designed to evaluate the efficacy of a
preoperative administration protocol of intravenous (IV) ferric
carboxymaltose (FCM) in colon cancer patients with iron de-
ficiency anemia. Evaluation was completed by assessing the
relative reduction in RBC transfusion requirements, post-
surgery complications (1 month after surgery), and the total
length of hospital stay compared with a retrospective cohort of
patients that had not received IV iron.
Material and methods
This is a non-interventional study conducted in Spain as a
multicenter survey involving two cohorts of consecutive pa-
tients with colon cancer and iron deficiency anemia. At diag-
nosis, the comparator group with no-IV iron treatment (no-IV
iron group) was obtained retrospectively while patients treated
with ferric carboxymaltose (FCM group) (Ferinject®; Vifor
Pharma España S.L.) were recorded prospectively.
Inclusion of prospective patients was completed between
February 2012 and September 2012 in a specialized hospital
setting at 11 Spanish hospitals. In the same participant centers,
the retrospective cohort was obtained in a sequential manner
from surgical intervention 2011 registries and independently
of outcomes. All subjects gave their informed consent prior to
their inclusion in the study. Approval by the appropriate
Institutional Review Boards was obtained.
The study population in both groups included patients aged
18 years or over, diagnosed with colon adenocarcinoma locat-
ed at least 15 cm above the anal margin, with elective surgery
programmed under curative purposes. Iron deficiency anemia
was defined according to WHO criteria (hemoglobin (Hb)
<13 g/dL in men and <12 g/dL in women) [22], serum ferritin
<30 ng/mL, and/or transferrin saturation index <20 %. There
were no restrictions on the surgical approach (laparoscopy,
open surgery, single port, etc.). The study excluded patients
who had rectal neoplasms, emergency or palliative surgery,
other linked illnesses associated with anemia such as renal
failure or hematological syndromes, tumor recurrence, or a
clinical history of blood transfusions during the past 30 days.
The primary outcome of the study was the relative reduc-
tion in perioperative and at 30-day postoperative allogenic
RBC transfusion requirements. The secondary end points in-
cluded the reduction of hospital length of stay (or time to
discharge), the incidence of postoperative complications reg-
istered during the first month after surgery, the evolution of
hemoglobin and iron parameters during the study period, and
the proportion of patients with normalized Hb levels and re-
sponse rate.
The physicians responsible for the patients’ care, surgery,
hospital discharge, and follow-up were unaware of study in-
terventions. When the center diagnosed a patient with colon
cancer and concurrent iron deficiency anemia, and who
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met all the selection criteria, the investigator requested the
inclusion of the patient in the program of IV iron with ferric
carboxymaltose administration. The total dose was obtained
using the ferric carboxymaltose product information dosing
scheme [16, 17]. Whenever possible, the FCM administration
was between 2 and 4 weeks before the scheduled surgery.
As standardized hospital clinical practice, a complete blood
test was also performed at diagnosis, the day of admission for
surgery, at discharge, and at 30 days post-surgery. Peri- and
postoperative RBC transfusions were based on the pertinent
blood tests and as in hospital clinical practice: being always
performed in patients with hemoglobin levels under 7 g/dL,
under physician criteria between 7 and 9 mg/dL, and not rec-
ommended over 9 g/dL. Normalized Hb levels were
established as ≥12 g/dL in women and ≥13 g/dL in men
[22]. Patient response was considered when Hb increases
≥1.5 g/dL.
Based on the primary end point, the calculated sample size
of the study was approximately 111 patients per group. This
estimated size allows the detection of at least a 20 % reduction
in RBC transfusion requirements with a statistical power of
90 % and using a 95 % confidence interval (CI). Continuous
end points were summarized using descriptive statistics: n,
mean, standard deviation, minimum, median and maximum,
95 % CI, and number of missing observations. For discrete
end points, the frequency and percentage for each response
category were calculated as well as 95 % CI and number of
missing data. Missing data was excluded when calculating
percentages relative to the total sample. Student t test or
Mann-Whitney U test were used depending on distribution
of variables.
Results
Baseline and clinical characteristics
Baseline characteristics were similar for both cohorts
studied (Table 1). In total, 266 patients were included:
111 received FCM (57.3 % males, mean age 72.9±11.1)
and 155 were in the no-IV iron group (55.8 % males,
mean age 70.8±10.3). Both groups were similar in terms
of tumor location, medical history, and surgical approach
and procedures, as well as the proportion of patients with
moderate or heavy blood loss (≥50 mL) during surgery
(Table 1). Anemia at diagnosis was more pronounced in
the FCM group.
All patients in the retrospective cohort (no-IV iron group)
were receiving different doses and formulations of oral iron
supplementation at the time of diagnosis. Within the prospec-
tive cohort, the median total FCM dose was 1000 mg iron
(mean 1275±430.1 mg) and the administration was 28.5±
16.7 days before surgery (mean±SD).
Table 1 Baseline, clinical, and surgical characteristics of the patients
No-IV iron FCM p
Number, N 155 111
Sex, male (%) 55.8 57.3 0.817
Age, years (mean±SD) 70.8±10.3 72.9±11.1 0.121






Past medical history (%)
Diabetes 35.7 29.2 0.276
Hypertension 56.2 56.0 0.968
EPOC 12.3 13.9 0.713
Heart disease 19.1 22.6 0.486
Anticoagulant therapy 7.9 15.7 0.050
Tumor location (%) 0.846
Ascending colon 55.6 59.2
Transverse colon 9.2 6.8
Descending colon 8.5 9.7





Anemic symptoms 43.2 36.9
None 14.2 23.4
Iron treatment at diagnosis (%)
Oral 100.0 15.3
Ferric carboxymaltose 0.0 100.0
Surgical approach (%) 0.105
Open surgery 52.6 42.7
Laparoscopy 47.4 54.5
Single-port surgery 0.0 0.9
NOTES 0.0 1.8
Surgical intervention (%) 0.838
Right hemicolectomy 61.4 64.0
Sigmoidectomy 24.1 21.0
Left hemicolectomy 9.0 11.0
Segmental resection 5.5 4.0
Intraoperative blood losses (%) 0.857
Low 47.1 43.3
Moderate (≥50 ml) 44.2 46.3
High (>250 ml) 8.7 10.4
Intraoperative moderate/severe blood losses (%)
Open surgery 62 73 0.356
Laparoscopic 43 39 0.817
ASA American Society of Anesthesiologists, BMI body mass index,
EPOC excess post-exercise oxygen consumption, FCM ferric
carboxymaltose, NOTES
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Primary outcome: transfusion requirements
A significantly lower percentage of patients in the FCM
group required allogenic RBC transfusion during the
study: 9.9 vs. 38.7 % (OR: 5.9, 95 % CI: 2.9–11.1,
p<0.001). This statistically and clinically significant dif-
ference was also observed in the individual peri- and
post-surgery periods until day 30 and independently of
the type of surgical approach (laparoscopic or open sur-
gery) (Table 2). Overall, the mean number of RBC units
transfused during the study period was statistically lower
in patients treated with FCM (0.2±0.5 vs. 0.8±0.4,
p<0.0001) (see Table 2 for peri- and post-surgery pe-
riods). When analyzed by surgery, FCM-treated patients
received statistically significant lower mean units of
RBC as well (Table 2). Throughout the entire study pe-
riod, 9 % of patients in the no-IV iron group received 4
or more RBC units vs. 0 % in the FCM group (p=
0.5817).
Evolution of hemoglobin and iron metabolism parameters
All the hematological parameters, except serum ferritin and
transferrin saturation index at hospital discharge, presented
significant differences between the FCM and no-IV iron
groups at admission time point and 1 month after surgery
(Table 3, Fig. 1). Importantly, the FCM group received overall
less RBC transfusions, and data has not been censored for
transfusions.
Figure 1 reflects the evolution of hemoglobin levels in
both groups at the four study-defined time points.
Despite the lower levels of hemoglobin at diagnosis for
the FCM group (9.6±1.4 vs. 10.0±1.2 g/dL, p<0.005),
and much lower RBC transfusion rate, significantly
higher hemoglobin concentrations were achieved by the
FCM group at hospital admission, discharge, and 30 days
post-surgery (Table 3; Fig. 1). Mean total hemoglobin
increases significantly favor the FCM group between di-
agnosis and hospital admission (1.5 vs. 0.5 g/dL;
p<0.0001) and between diagnosis and 30 days post-
surgery (3.1 vs. 1.5 g/dL; p<0.0001). This was also the
case when doing the analysis for transfused and non-
transfused patients: mean total hemoglobin increase be-
tween diagnosis and 30 days post-surgery in transfused
patients was 3.5±1.9 FCM vs. 1.4±1.6 no-IV (p<0.05)
and in non-transfused patients was 3.1±1.9 FCM vs. 1. 6
±1.8 no-IV (p<0.001).
A similar percentage of patients with Hb≤10 g/dL was
observed at diagnosis (79 %) in both groups. This rate
descends by nearly 20 % for the no-IV group and 30 %
in the FCM group at time of hospital admission. The
percentage of patients with Hb≤10 g/dL was significant-
ly lower in the FCM group at hospital discharge (61.6 %
FCM vs. 75.7 % no-IV iron, p<0.05) and at 30 days
post-surgery (12.0 % FCM group vs. 28.9 % no-IV iron,
p<0.05). Furthermore, the percentage of patients with
normalized hemoglobin at 30 days post-surgery was sig-
nificantly higher in the FCM group vs. no-IV iron (40.0
vs. 26.7 %, p<0.05).
Figure 1 also shows the evolution of serum ferritin
levels. At 30 days after-surgery, the average FCM-
treated patient presented no recognizable signs of iron
deficiency anemia (being the mean of Hb: 12.6 g/dL
[≥12 g/dL]; serum ferritin: 218 ng/mL [≥30 ng/mL]; and
saturation transferrin index: 25.1 % [≥20 %]) compared
with the no-IV group that did not reach normalized mean
values (Table 3).
Figure 2 illustrates how the percentage of hemoglobin re-
sponders (Hb increase of ≥1.5 g/dL) significantly increased in
the group treated with FCM compared to the no-IV group:
Table 2 Need for allogenic RBC
transfusion (percentage of
patients) and mean RBC units
transfused
No-IV iron FCM p
Need for RBC transfusion (overall), % 38.7 9.9 <0.001
Need for RBC transfusions (peri-surgery period), % 31.8 8.3 <0.001
Need for RBC transfusion (post-surgery until day 30), % 16.7 5.0 0.005
Need for RBC transfusion (by surgery), %
Open surgery, % 37.7 17.1 <0.05
Laparoscopic, % 25.4 0.0 <0.0001
Mean units of RBC transfused (overall) 0.8 0.2 <0.0001
Mean units of RBC transfused (peri-surgery) 0.5 0.1 <0.0001
Mean units of RBC transfused (post-surgery until day 30) 0.3 0.1 <0.05
Mean units of RBC transfused (by surgery)
Open surgery 1.0 0.4 <0.01
Laparoscopic 0.6 0.0 <0.0001
FCM ferric carboxymaltose, RBC red blood cell
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48.1 vs. 20.0 % between diagnosis and hospital admission
(p<0.0001) and 80.0 vs. 48.9 % between diagnosis and
30 days after surgery (p<0.0001).
Post-surgery complications
A numerically lower total number of reinterventions and
complications related to surgery (including suture dehis-
cence, paralytic ileus, hemoperitoneum, rectal bleeding,
thromboembolism, etc.) at 30 days after surgery were
seen in the FCM group in comparison with no-IV pa-
tients: 20.7 vs. 26.5 % (OR=1.4; 95 % CI: 0.8–2.4; p=
0.311) (Table 4).
Impact on hospital stay
The length of hospital stay, measured from the day of
surgery until the day of discharge, is shown in Fig. 3.
Table 3 Mean (±SD)
hemoglobin, hematocrit, MCV,
and iron parameters at different
time points before and after













No-IV iron 10.0±1.2 31.8±3.4 20.0±20.8 7.6±4.9 78.4±8.6
FCM 9.6±1.4** 31.1±3.9 39.6±62.9 8.0±5.9 79.3±8.2**
Hospital admission
No-IV iron 10.5±1.3 33.1±3.9 24.0±21.6 7.9±3.1 80.6±7.9
FCM 11.0±1.7* 34.9±5.0* 296.6±292.1*** 19.1±11.6*** 84.5±7.3***
Hospital discharge
No-IV iron 10.3±1.2 32.1±3.5 305.0±323.6 16.9±15.4 82.6±6.9
FCM 10.7±1.4* 33.4±4.4* 298.1±294.5 18.2±10.5 86.4±6.6***
30 days post-surgery
No-IV iron 11.6±1.3 36.4±5.9 102.1±210.1 15.9±13.3 83.0±7.4
FCM 12.6±1.3*** 38.8±3.7*** 218.1±218.3* 25.1±18.2* 88.6±5.3***
FCM ferric carboxymaltose, s-ferritin serum ferritin, T-SAT transferrin saturation index (%),MCVmean corpus-
cular volume (10−15 L)

























































Fig. 1 Evolution of hemoglobin
levels (g/dL) at four time points:
diagnosis, hospital admission,
discharge, and 30 days post-
surgery. Groups were not
censored for transfusions.
Significant differences between
groups are marked with an
asterisk for Hb and dagger for
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The FCM group had a significantly shorter mean length
of hospital stay: 8.4±6.8 days compared to the no-IV
iron group (10.9±12.4 days) (p<0.001). Overall, patients
that required RBC transfusion had a longer hospital stay
than patients without transfusion (FCM 9.2±9.4 days vs.
no-IV iron 12.0±13.0 days; p<0.005).
Safety of ferric carboxymaltose
From the FCM-treated patients, no deaths, hypersensitiv-
ity, or other serious adverse drug reactions were
observed.
Discussion
Preoperative anemia in patients with surgical bleeding
risk associated with colorectal cancer has proved very
prevalent and is an independent risk factor for the re-
quirements of allogeneic RBC transfusion [12]. Under
this global perspective, and considering the lack of con-
trolled studies with a significant number of patients, our
prospectively defined and treated population demonstrat-
ed a significant clinical benefit for the preoperative ad-
ministration of an IV iron supplementation using ferric





































Fig. 2 Percentage of hemoglobin
responders—defined as those
with an Hb increase of ≥1.5 g/
dL—at hospital admission and
30 days post-surgery with respect
to Hb diagnosis levels. Data was
not censored for transfusions
Table 4 Incidence of post-









Suture failure 32.4 21.7
Paralytic ileus 24.3 17.4
Rectorrhagia 16.2 8.7
Hemoperitoneum 10.8 4.3
Thromboembolic complication 10.8 0.0
Surgical reintervention (% patients) 13.4 6.7 NS
Hospital readmission (surgical-related cause) (% patients) 3.9 4.0 NS
FCM ferric carboxymaltose, NS non-significant
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cohort (with similar baseline characteristics). This overall
fourfold reduction of transfusions (and hence associated
risk factors) was achieved using FCM which was well
tolerated in this group of patients and demonstrated a
favorable benefit-risk profile. Furthermore, the observed
needs for transfusion were f ive t imes (pre-and
in t raopera t ive ) and a lmos t th ree t imes h igher
(postoperative) for the group that had not received IV
iron. Interestingly, the patients in this cohort were all
receiving oral iron supplementation at time of diagnosis.
Similar decreases in transfusion requirements for FCM-
treated patients have been reported in a study that compares
the pre-operative administration of FCM with the IV iron su-
crose administration in a small cohort of 45 patients treated for
anemia in colon cancer resection [18]. In this study, Bisbe and
collaborators observed a noticeable reduction in the percent-
age of patients that required RBC transfusion in the FCM
group (from 40 % with iron sucrose to 7 % with FCM), as
well as fewer iron administration sessions (as FCM may be
administered at a single dose of 1000 mg iron per session vs.
only 200 mg for iron sucrose). Analogously, similar trends in
reducing allogenic RBC transfusion requirements were ob-
served with FCM in a three-cohort retrospective study that
included a total number of 154 patients with GI cancer sub-
mitted to laparoscopic resection (gastrectomy, right or left
colectomy, or rectum resection) [23]. Even though initial
levels of Hb were higher in the non-anemic group of patients,
the anemic FCM group required similar mean RBC units
transfused, and both were significantly lower (p<0.001) than
in the anemic no-IV-treated group (0.5, 0.4, and 2.4,
respectively).
In contrast, a previous randomized placebo-control
clinical trial (n=60) did not find support for the use of
intravenous iron sucrose (600 mg iron in two divided
doses, 14 days before surgery) as a preoperative supple-
mentation to reduce the likelihood of allogenic RBC
transfusion for patients undergoing resectional surgery
for colorectal cancer (19.2 % placebo vs. 5.9 % in iron
sucrose; p=0.335) [24]. However, although not reaching
statistical significance, the number of transfusions was
still numerically higher in the placebo group, and it
might be hypothesized that the administered iron doses
were not sufficient to meet the iron deficit in these
patients.
Within our study, and even despite significantly fewer pa-
tients transfused, at 1 month post-surgery, as overall, the
FCM-treated patients did not reflect signs of anemia, as well
as no signs of iron deficiency (mean ferritin and transferrin
saturation index were at normal values). Our data in a large
patient group extends to the 30-day post-surgery period the
previously found evidence for improved hemoglobin concen-
trations and reduced transfusions in gastrointestinal cancer
patients with anemia treated with FCM [23]. Moreover, in
those anemic patients included in our study who have received
FCM, almost one out of two reached normalized hemoglobin
levels after 1 month from the colon cancer resection and de-
spite their lower mean hemoglobin levels at diagnosis and
their lower rate of transfusion requirement, while in patients
with no-IV iron administration, this percentage was only
around 26 %. Our data further supports the preoperative treat-
ment with ferric carboxymaltose in anemic colon cancer pa-
tients who are planned for surgery, with benefits extending
until 30 days post-surgery.
In addition to the reduction in transfusion require-
ments and the improved iron parameters, our study dem-
onstrates for the first time the benefit of a preoperative
FCM administration strategy in the peri- and post-
surgery periods when treating this kind of patients.
Specifically, importance should be given to the observed
relation to the mean hospital length of stay which was
significantly reduced with the FCM administration by a
mean total of 2.5 days. Likewise, the postoperative ben-
efits of intravenous iron administered previously to the
surgery have been reported recently in other patient pro-
files, i.e., those submitted to non-cardiac surgery, gyne-
cological tumor resection, cardiac valve replacement, and
orthopedic procedures in terms of reduction of post-
surgery complications and reduced hospital length of stay
[10, 16, 19, 20, 25]. Finally, it has ruled out any link
between the surgical approach and possible differences
between groups with regard to complications in the 30-
day post-surgery period.
As a result of these improvements, pretreatment with FCM
in anemic colon cancer patients seems to be a cost-effective
intervention. The incremental costs of IV iron treatment are




















Fig. 3 Mean length of hospital stay measured from the day of surgery
until the hospital discharge
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length of stay and transfusion rates. The extent of this eco-
nomic advantage will be assessed in a further within-trial anal-
ysis. In a previous Spanish cost analysis taking into account
both drug acquisition costs of FCM and iron sucrose as well as
administration costs in anemic patients undergoing major
elective surgery, the final cost benefit of FCM administration
per treatment compared with the common IV iron sucrose
therapy was demonstrated by providing amean of €63 savings
per patient FCM treatment [18].
As strengths of our study, it should be mentioned the num-
ber of patients considered for the analysis in the predefined
groups as well as their homogenous baseline and clinical char-
acteristics in both groups. It is also important to highlight that
the significant trends observed in the measured outcomeswere
achieved after similar laboratory values at diagnosis and sur-
gical characteristics in both groups, although the FCM group
showed a slightly reduced hemoglobin at baseline. The pres-
ent study has several limitations that warrant acknowledg-
ment. Specifically, the non-randomized design limits the in-
terpretation of the results. However, these patients represent
“real-life” clinical practice, and hence, this is also a strength of
this research. Future randomized controlled trial(s) focused on
the use of FCM treatment in preoperative anemic colorectal
cancer patients vs. a similar active supplement may aid to
confirm our findings.
In conclusion, our data demonstrate that preoperative ferric
carboxymaltose treatment in iron-deficient colon cancer pa-
tients with anemia significantly reduced the length of hospi-
talization, decreased both the perioperative and postoperative
allogenic RBC transfusion requirements, showed no signs of
iron deficiency anemia at 30 days post-surgery, and was safe
and well tolerated. Based on reduction of RBC transfusions
and length of hospital stay, it can be assumed that the preop-
erative administration of ferric carboxymaltose in iron-
deficient colon cancer patients with anemia undergoing sur-
gery could result in significant cost savings.
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